Pharmafile Logo

Zykadia

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

- PMLiVE

Novartis announces new data supporting MS therapy Kesimpta

The latest trial results reinforce the drug's long-term efficacy and safety profile

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

- PMLiVE

Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

The companies will focus on inflammatory diseases that have been historically difficult to treat

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links